Strongest human evidence The METAOD006 (OPTIONS) Phase 2b trial randomized 502 adults with obesity (BMI 30-45 kg/m^2) to oral AOD-9604 (0.25, 0.5, or 1 mg/day) or placebo for 24 weeks alongside a supervised diet and exercise program
This multi-receptor approach may lead to greater appetite control, increased fat burning, and potentially more weight loss over time compared to semaglutide alone
Lifestyle and dietary interventions for Mnire's disease
GHK-Cu stimulates collagen and glycosaminoglycan synthesis, directly increasing skin density and elasticity
For a 5 mg vial, 2 mL creates 2,500 mcg/mL, a popular ratio for easy dosing
The powder inside that vial is delicate